Liver Cancer Diagnostics Market was valued at USD 12.53 Billion in 2023 and is expected to reach USD 21.3 Billion by 2030, Growing at a CAGR of 7.9% from 2023 to 2030.

The Liver Cancer Diagnostics Market is a segment of the healthcare industry that involves the development and sales of diagnostic tests and technologies used to detect liver cancer, also known as hepatocellular carcinoma (HCC). The market for liver cancer diagnostics is expected to grow in the coming years due to several factors, including an increasing prevalence of liver cancer, advances in diagnostic technologies, and a growing focus on early detection and prevention of the disease.

There are several diagnostic tests and technologies used to detect liver cancer, including imaging tests (such as ultrasound, CT scan, and MRI), blood tests (such as alpha-fetoprotein [AFP] and cancer antigen 19-9 [CA 19-9]), and tissue biopsy (removal of a small sample of tissue for examination under a microscope). In recent years, there have been significant advances in the development of non-invasive diagnostic methods, such as elastography and contrast-enhanced ultrasound, which can provide detailed images of the liver without the need for a biopsy. Factors that are expected to drive the growth of the liver cancer diagnostics market include an aging population (liver cancer is more common in older people), an increasing prevalence of risk factors for liver cancer (such as hepatitis B and C infections and alcoholic liver disease), and a growing focus on early detection and prevention of the disease.

The COVID-19 pandemic has had a significant impact on the liver cancer diagnostics market, as well as the healthcare industry as a whole. The pandemic has disrupted the supply chains of diagnostic tests and technologies, leading to shortages and delays in testing. In addition, the pandemic has resulted in a decline in the number of elective surgeries and diagnostic procedures being performed, as hospitals and clinics prioritize the treatment of COVID-19 patients and implement measures to reduce the risk of transmission of the virus. The COVID-19 pandemic has also led to a decline in the demand for diagnostic tests and technologies, as non-essential healthcare services were postponed or cancelled in an effort to reduce the burden on the healthcare system. This has resulted in a decline in revenue for companies operating in the liver cancer diagnostics market.

However, the COVID-19 pandemic has also led to an increase in the demand for diagnostic tests and technologies as a means of detecting and monitoring the spread of the virus. Many diagnostic companies have pivoted to focus on the development and production of COVID-19 tests, which has helped to offset some of the decline in demand for other diagnostic tests and technologies.

Global Liver Cancer Diagnostics Market Segmentation

Liver Cancer Diagnostics Market is expected to grow in the coming years due to several factors, including an increasing prevalence of liver cancer, advances in diagnostic technologies, and a growing focus on early detection and prevention of the disease.

Type

• Laboratory Tests
• Biomarkers
• Oncofetal and Glycoprotein Antigens
• Enzymes and Isoenzymes
• Growth Factors and Receptors
• Molecular Markers
• Pathological Biomarkers
• Blood Tests
• Imaging Tests
• Endoscopy
• Biopsy
• Others

End User

• Hospitals
• Diagnostics Centers
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Others

Competitive Landscape and Liver Cancer Diagnostics Market

•  Abbott Laboratories
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Qiagen N.V.
• Seimens Healthineers
• Becton, Dickinson & Company
• Illumina, Inc.
• Epigenomics AG
• Koninklijke Philips N.V.
• Fujifilm Medical Systems U.S.A

Recent Developments in the field of liver cancer diagnostics. Some of these developments include:

Non-invasive diagnostic methods:

In recent years, there have been significant advances in the development of non-invasive diagnostic methods for detecting liver cancer, such as elastography and contrast-enhanced ultrasound. These methods can provide detailed images of the liver without the need for a biopsy, which is a major advantage as biopsy is an invasive procedure that carries some risks.

Biomarkers: 

There have been several recent developments in the field of biomarkers for detecting liver cancer. For example, researchers have identified a panel of biomarkers that can accurately predict the risk of HCC development in patients with chronic hepatitis B infection. In addition, there have been advances in the development of blood tests for detecting liver cancer using biomarkers, such as alpha-fetoprotein (AFP) and cancer antigen 19-9 (CA 19-9).

Molecular markers: 

Researchers have identified several molecular markers that are specific to liver cancer and could be used to improve the accuracy of diagnostic tests. For example, researchers have identified a panel of four molecular markers that can accurately predict the presence of HCC in patients with chronic hepatitis B infection.

Artificial intelligence (AI) and machine learning:

There have been several recent developments in the use of AI and machine learning for detecting liver cancer. For example, researchers have developed AI algorithms that can analyze imaging tests, such as ultrasound and CT scans, to detect liver cancer with high accuracy. In addition, researchers are exploring the use of machine learning algorithms to analyze biomarker data to improve the accuracy of diagnostic tests for liver cancer.

Overall, these recent developments have the potential to improve the accuracy and efficiency of diagnostic tests for liver cancer, which could lead to earlier detection and better outcomes for patients.

Type Insights

Laboratory Tests: 

The segment of laboratory tests is expected to continue to be a significant contributor to the growth of the liver cancer diagnostics market. Laboratory tests are widely used to diagnose and monitor liver cancer, and advances in technology have made them more accurate and efficient.

Biomarkers:

The segment of biomarkers is also expected to experience strong growth, as these substances can be used to detect liver cancer at an early stage and monitor the progress of the disease. Biomarkers are being increasingly used to improve the accuracy of diagnostic tests and to guide treatment decisions.

Blood tests:

Blood tests are a widely used diagnostic tool for detecting liver cancer, and the segment is expected to continue to grow as new biomarkers are developed and existing tests become more accurate.

Imaging tests:

The segment of imaging tests is expected to experience strong growth due to advances in technology that have made these tests more accurate and efficient. Imaging tests are widely used to detect liver cancer and to monitor the progress of the disease.

Endoscopy:

The segment of endoscopy is expected to experience moderate growth as this procedure is often used to confirm a diagnosis of liver cancer and to guide treatment decisions.

Biopsy:

The segment of biopsy is expected to experience moderate growth as this procedure is often used to confirm a diagnosis of liver cancer and to guide treatment decisions.

Others:

The segment of other diagnostic tests and technologies is expected to experience moderate growth as new technologies are developed and become more widely available.

End user Insights

Hospitals: 

Hospitals are expected to continue to be the largest end user of liver cancer diagnostic tests and technologies, as they are the primary providers of diagnostic services.

Diagnostics centers: 

The segment of diagnostics centers is expected to experience strong growth as these facilities specialize in providing diagnostic tests and technologies, including those used to detect liver cancer.

Diagnostic imaging centers:

The segment of diagnostic imaging centers is expected to experience strong growth as these facilities specialize in providing imaging tests, such as ultrasound, CT scan, and MRI, which can be used to detect liver cancer.

Cancer research institutes:

The segment of cancer research institutes is expected to experience moderate growth as these organizations conduct research on cancer, including the development of diagnostic tests and technologies for detecting liver cancer.

Frequently Asked Questions (FAQ) About the Liver Cancer Diagnostics Market:

• What are the most common diagnostic tests and technologies used to detect liver cancer?

The most common diagnostic tests and technologies used to detect liver cancer include imaging tests (such as ultrasound, CT scan, and MRI), blood tests (such as alpha-fetoprotein [AFP] and cancer antigen 19-9 [CA 19-9]), and tissue biopsy (removal of a small sample of tissue for examination under a microscope). In recent years, there have been significant advances in the development of non-invasive diagnostic methods, such as elastography and contrast-enhanced ultrasound, which can provide detailed images of the liver without the need for a biopsy.

• What are the key drivers of growth in the liver cancer diagnostics market?

The key drivers of growth in the liver cancer diagnostics market include an increasing prevalence of liver cancer, advances in diagnostic technologies, and a growing focus on early detection and prevention of the disease.

• How has the COVID-19 pandemic impacted the liver cancer diagnostics market?

The COVID-19 pandemic has had a significant impact on the liver cancer diagnostics market, as well as the healthcare industry as a whole. The pandemic has disrupted the supply chains of diagnostic tests and technologies, leading to shortages and delays in testing. In addition, the pandemic has resulted in a decline in the number of elective surgeries and diagnostic procedures being performed, as hospitals and clinics prioritize the treatment of COVID-19 patients and implement measures to reduce the risk of transmission of the virus. However, the COVID-19 pandemic has also led to an increase in the demand for diagnostic tests and technologies as a means of detecting and monitoring the spread of the virus.

• What are the key segments of the global liver cancer diagnostics market?

The key segments of the global liver cancer diagnostics market include by type (laboratory tests, biomarkers, blood tests, imaging tests, endoscopy, biopsy, and others) and by end user (hospitals, diagnostics centers, diagnostic imaging centers, and cancer research institutes).

• What are the key regional markets for liver cancer diagnostics?

The key regional markets for liver cancer diagnostics include the Asia-Pacific region, North America, and Europe. The Asia-Pacific region is expected to be the largest and fastest-growing market, due to factors such as a large and rapidly aging population, a high prevalence of risk factors for liver cancer, and an increasing focus on early detection and prevention of the disease. The North American and European regions are also expected to be significant markets, due to factors such as a large and aging population and an increasing focus on early detection and prevention of liver cancer.

Regional insights

Asia-Pacific region is expected to be the largest and fastest-growing market for liver cancer diagnostics, due to factors such as a large and rapidly aging population, a high prevalence of risk factors for liver cancer (such as hepatitis B and C infections and alcoholic liver disease), and an increasing focus on early detection and prevention of the disease.

The North American region is also expected to be a significant market for liver cancer diagnostics, due to factors such as a large and aging population and a high prevalence of risk factors for liver cancer. The European region is also expected to be a significant market, due to a large and aging population and an increasing focus on early detection and prevention of liver cancer.

North America

• U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa